Mirova US LLC Has $350.32 Million Position in Eli Lilly and Company (NYSE:LLY)

Mirova US LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 13.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 600,966 shares of the company’s stock after selling 89,499 shares during the period. Eli Lilly and Company makes up approximately 5.3% of Mirova US LLC’s portfolio, making the stock its 9th largest position. Mirova US LLC’s holdings in Eli Lilly and Company were worth $350,315,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Fairfield Bush & CO. bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $107,000. Roundview Capital LLC grew its position in Eli Lilly and Company by 2.6% in the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after purchasing an additional 53 shares during the period. Merit Financial Group LLC bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $210,000. NewEdge Advisors LLC grew its position in Eli Lilly and Company by 9.9% in the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after purchasing an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $561,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on LLY shares. Truist Financial reaffirmed a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $728.05.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $4.03 during trading hours on Wednesday, reaching $746.74. The company’s stock had a trading volume of 2,569,799 shares, compared to its average volume of 2,215,511. The firm has a 50 day moving average price of $763.51 and a 200-day moving average price of $657.01. Eli Lilly and Company has a one year low of $367.35 and a one year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a market cap of $709.52 billion, a P/E ratio of 128.75, a P/E/G ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the previous year, the firm posted $2.09 EPS. The business’s quarterly revenue was up 28.1% on a year-over-year basis. On average, analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.